 Ellen Gravallese
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 26 | 2020 | 214 | 7.630 |
Why?
| | Bone Resorption | 10 | 2015 | 39 | 3.710 |
Why?
| | Osteoclasts | 12 | 2015 | 56 | 2.090 |
Why?
| | Arthritis, Experimental | 8 | 2016 | 34 | 1.990 |
Why?
| | Osteoblasts | 7 | 2015 | 155 | 1.880 |
Why?
| | Bone Remodeling | 3 | 2014 | 26 | 1.190 |
Why?
| | Cytokines | 8 | 2015 | 717 | 1.130 |
Why?
| | RNA | 2 | 2020 | 282 | 0.980 |
Why?
| | Inflammation | 8 | 2014 | 651 | 0.970 |
Why?
| | Bone and Bones | 7 | 2014 | 105 | 0.960 |
Why?
| | Bone Density | 3 | 2017 | 134 | 0.950 |
Why?
| | Tumor Necrosis Factor-alpha | 7 | 2017 | 490 | 0.880 |
Why?
| | Spondylarthropathies | 2 | 2010 | 5 | 0.830 |
Why?
| | Teriparatide | 1 | 2017 | 4 | 0.800 |
Why?
| | Bone Diseases, Metabolic | 1 | 2017 | 23 | 0.790 |
Why?
| | Bone Density Conservation Agents | 1 | 2017 | 45 | 0.770 |
Why?
| | Autoantibodies | 3 | 2015 | 117 | 0.760 |
Why?
| | Osteogenesis | 4 | 2012 | 87 | 0.760 |
Why?
| | Endodeoxyribonucleases | 3 | 2016 | 34 | 0.750 |
Why?
| | Wnt Proteins | 3 | 2012 | 93 | 0.750 |
Why?
| | Toll-Like Receptors | 2 | 2015 | 423 | 0.700 |
Why?
| | Joints | 4 | 2012 | 24 | 0.660 |
Why?
| | Spondylitis, Ankylosing | 2 | 2014 | 16 | 0.660 |
Why?
| | Antibody Formation | 1 | 2014 | 103 | 0.650 |
Why?
| | Rheumatology | 2 | 2003 | 30 | 0.580 |
Why?
| | Inflammation Mediators | 4 | 2015 | 133 | 0.580 |
Why?
| | DNA-Binding Proteins | 4 | 2014 | 1002 | 0.570 |
Why?
| | Methotrexate | 1 | 2011 | 71 | 0.520 |
Why?
| | Animals | 23 | 2016 | 14740 | 0.510 |
Why?
| | Antirheumatic Agents | 5 | 2017 | 114 | 0.500 |
Why?
| | Humans | 29 | 2020 | 33464 | 0.480 |
Why?
| | Bone Diseases | 1 | 2009 | 20 | 0.450 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2009 | 62 | 0.440 |
Why?
| | Sialoglycoproteins | 2 | 2004 | 20 | 0.380 |
Why?
| | Mice | 15 | 2016 | 7406 | 0.360 |
Why?
| | Disease Models, Animal | 7 | 2016 | 1198 | 0.350 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2005 | 69 | 0.340 |
Why?
| | Severity of Illness Index | 5 | 2017 | 841 | 0.340 |
Why?
| | Arthritis | 3 | 2015 | 37 | 0.330 |
Why?
| | Signal Transduction | 7 | 2015 | 2274 | 0.330 |
Why?
| | Autoimmunity | 2 | 2016 | 141 | 0.330 |
Why?
| | Glycoproteins | 4 | 2009 | 172 | 0.320 |
Why?
| | Diphosphonates | 1 | 2004 | 31 | 0.320 |
Why?
| | Treatment Outcome | 6 | 2017 | 2592 | 0.320 |
Why?
| | Peer Review, Research | 1 | 2003 | 31 | 0.290 |
Why?
| | Conflict of Interest | 1 | 2003 | 25 | 0.290 |
Why?
| | Disclosure | 1 | 2003 | 34 | 0.290 |
Why?
| | Truth Disclosure | 1 | 2003 | 45 | 0.290 |
Why?
| | Editorial Policies | 1 | 2003 | 26 | 0.290 |
Why?
| | Mice, Inbred C57BL | 8 | 2016 | 2300 | 0.280 |
Why?
| | Societies, Medical | 1 | 2003 | 154 | 0.270 |
Why?
| | Receptors, Tumor Necrosis Factor | 5 | 2005 | 62 | 0.270 |
Why?
| | Mice, Knockout | 6 | 2016 | 1616 | 0.260 |
Why?
| | Membrane Glycoproteins | 4 | 2015 | 619 | 0.250 |
Why?
| | Cell Differentiation | 4 | 2014 | 1032 | 0.250 |
Why?
| | Radiography | 2 | 2013 | 302 | 0.240 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2012 | 101 | 0.240 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 3 | 2005 | 118 | 0.230 |
Why?
| | Toll-Like Receptor 7 | 2 | 2015 | 67 | 0.210 |
Why?
| | Proto-Oncogene Proteins | 3 | 2005 | 272 | 0.200 |
Why?
| | Ulna | 1 | 2017 | 4 | 0.200 |
Why?
| | Radius | 1 | 2017 | 6 | 0.200 |
Why?
| | Metacarpophalangeal Joint | 1 | 2017 | 4 | 0.200 |
Why?
| | Female | 10 | 2017 | 18403 | 0.200 |
Why?
| | Cohort Studies | 2 | 2013 | 1363 | 0.200 |
Why?
| | Middle Aged | 8 | 2017 | 9665 | 0.190 |
Why?
| | Osteoprotegerin | 3 | 2005 | 9 | 0.190 |
Why?
| | Carrier Proteins | 3 | 2014 | 614 | 0.180 |
Why?
| | Interleukin-1beta | 2 | 2015 | 184 | 0.180 |
Why?
| | Male | 10 | 2017 | 16904 | 0.180 |
Why?
| | Hand Bones | 1 | 2016 | 2 | 0.180 |
Why?
| | Hand Joints | 1 | 2016 | 2 | 0.180 |
Why?
| | Aged | 5 | 2017 | 7462 | 0.180 |
Why?
| | Stromal Cells | 1 | 2016 | 50 | 0.180 |
Why?
| | Toll-Like Receptor 3 | 1 | 2015 | 59 | 0.180 |
Why?
| | Interferon Regulatory Factors | 1 | 2015 | 39 | 0.170 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2015 | 76 | 0.170 |
Why?
| | Phenotype | 2 | 2015 | 781 | 0.170 |
Why?
| | Myeloid Cells | 1 | 2015 | 54 | 0.170 |
Why?
| | Toll-Like Receptor 5 | 1 | 2014 | 9 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 2 | 2017 | 842 | 0.160 |
Why?
| | Myeloid Progenitor Cells | 1 | 2014 | 13 | 0.160 |
Why?
| | Acid Phosphatase | 2 | 2012 | 9 | 0.160 |
Why?
| | Endosomes | 1 | 2015 | 139 | 0.160 |
Why?
| | Peritonitis | 1 | 2014 | 22 | 0.160 |
Why?
| | Peritoneum | 1 | 2014 | 28 | 0.160 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 209 | 0.160 |
Why?
| | Blood Sedimentation | 1 | 2014 | 9 | 0.160 |
Why?
| | Cluster Analysis | 1 | 2014 | 198 | 0.160 |
Why?
| | Collagen Type II | 1 | 2014 | 10 | 0.160 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 1 | 2014 | 21 | 0.160 |
Why?
| | Autoantigens | 1 | 2014 | 93 | 0.160 |
Why?
| | Isoenzymes | 2 | 2012 | 132 | 0.160 |
Why?
| | Gadolinium | 1 | 2014 | 54 | 0.160 |
Why?
| | Interleukin-1 | 3 | 2003 | 147 | 0.150 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 3 | 2014 | 11 | 0.150 |
Why?
| | DNA | 2 | 2015 | 612 | 0.150 |
Why?
| | RANK Ligand | 3 | 2014 | 25 | 0.150 |
Why?
| | Immunohistochemistry | 4 | 2009 | 752 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2014 | 164 | 0.140 |
Why?
| | Synovial Membrane | 2 | 2003 | 20 | 0.140 |
Why?
| | Macrophages | 3 | 2014 | 731 | 0.140 |
Why?
| | Mice, Transgenic | 3 | 2012 | 948 | 0.140 |
Why?
| | Contrast Media | 1 | 2014 | 232 | 0.140 |
Why?
| | Hip Joint | 2 | 2009 | 24 | 0.140 |
Why?
| | Terminology as Topic | 1 | 2013 | 102 | 0.140 |
Why?
| | Bone Regeneration | 1 | 2012 | 9 | 0.140 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 468 | 0.140 |
Why?
| | Follistatin-Related Proteins | 1 | 2012 | 19 | 0.140 |
Why?
| | Transcription Factors | 3 | 2005 | 1203 | 0.140 |
Why?
| | Collagen | 3 | 2014 | 119 | 0.130 |
Why?
| | In Situ Hybridization | 2 | 2009 | 195 | 0.130 |
Why?
| | DNA Primers | 2 | 2009 | 301 | 0.130 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 339 | 0.120 |
Why?
| | RNA, Messenger | 6 | 2006 | 1248 | 0.120 |
Why?
| | Metacarpal Bones | 1 | 2009 | 1 | 0.120 |
Why?
| | Immunity, Innate | 1 | 2014 | 540 | 0.120 |
Why?
| | Calcification, Physiologic | 1 | 2009 | 12 | 0.120 |
Why?
| | Spondylarthritis | 1 | 2009 | 4 | 0.120 |
Why?
| | Rheumatic Diseases | 1 | 2009 | 21 | 0.110 |
Why?
| | Hand | 1 | 2009 | 39 | 0.110 |
Why?
| | Spine | 1 | 2009 | 40 | 0.110 |
Why?
| | Base Sequence | 2 | 2009 | 1246 | 0.110 |
Why?
| | Monocytes | 2 | 2014 | 303 | 0.110 |
Why?
| | Antibodies | 2 | 2014 | 151 | 0.110 |
Why?
| | Linear Models | 1 | 2009 | 331 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 438 | 0.100 |
Why?
| | Chondrocytes | 2 | 2005 | 41 | 0.100 |
Why?
| | Cartilage | 2 | 2005 | 24 | 0.100 |
Why?
| | Fractures, Bone | 1 | 2009 | 113 | 0.100 |
Why?
| | Health Surveys | 1 | 2009 | 259 | 0.100 |
Why?
| | Mice, Inbred DBA | 3 | 2014 | 83 | 0.100 |
Why?
| | NF-kappa B | 2 | 2014 | 388 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2009 | 675 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2009 | 712 | 0.100 |
Why?
| | Osteopontin | 2 | 2004 | 18 | 0.100 |
Why?
| | Cathepsins | 2 | 2006 | 29 | 0.090 |
Why?
| | Osteolysis | 1 | 2006 | 20 | 0.090 |
Why?
| | Prosthesis Implantation | 1 | 2006 | 20 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2011 | 291 | 0.090 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2005 | 7 | 0.090 |
Why?
| | Arthroplasty, Replacement | 1 | 2006 | 17 | 0.090 |
Why?
| | Prostaglandins | 1 | 2005 | 32 | 0.090 |
Why?
| | Collagenases | 1 | 2005 | 15 | 0.090 |
Why?
| | Synovial Fluid | 2 | 2015 | 26 | 0.090 |
Why?
| | Enzyme Induction | 1 | 2005 | 36 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 27 | 0.090 |
Why?
| | Osteoarthritis | 2 | 2003 | 31 | 0.090 |
Why?
| | Disease Progression | 2 | 2004 | 471 | 0.080 |
Why?
| | Lipopolysaccharides | 2 | 2005 | 519 | 0.080 |
Why?
| | Membrane Transport Proteins | 2 | 2016 | 100 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2005 | 117 | 0.080 |
Why?
| | Imidazoles | 1 | 2004 | 56 | 0.080 |
Why?
| | Angiopoietin-1 | 1 | 2004 | 2 | 0.080 |
Why?
| | Autoimmune Diseases | 1 | 2004 | 155 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 221 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 2004 | 782 | 0.070 |
Why?
| | Still's Disease, Adult-Onset | 1 | 2002 | 2 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2016 | 425 | 0.070 |
Why?
| | Epitopes | 1 | 2003 | 249 | 0.070 |
Why?
| | Risk Factors | 1 | 2009 | 2937 | 0.070 |
Why?
| | Trans-Activators | 1 | 2003 | 282 | 0.060 |
Why?
| | Immunoglobulin G | 1 | 2002 | 334 | 0.060 |
Why?
| | Receptors, Interleukin-1 | 2 | 2015 | 64 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-ets | 3 | 2005 | 19 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2014 | 1805 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2005 | 268 | 0.060 |
Why?
| | Phosphorylation | 2 | 2014 | 670 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 519 | 0.050 |
Why?
| | Promoter Regions, Genetic | 3 | 2005 | 576 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 1235 | 0.050 |
Why?
| | Membrane Proteins | 2 | 2016 | 650 | 0.040 |
Why?
| | Radiation Chimera | 1 | 2016 | 55 | 0.040 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2015 | 5 | 0.040 |
Why?
| | Splenomegaly | 1 | 2015 | 15 | 0.040 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2015 | 32 | 0.040 |
Why?
| | Adult | 4 | 2016 | 9425 | 0.040 |
Why?
| | Cell Line | 3 | 2005 | 1759 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 140 | 0.040 |
Why?
| | Flagellin | 1 | 2014 | 8 | 0.040 |
Why?
| | Toll-Like Receptor 2 | 1 | 2015 | 233 | 0.040 |
Why?
| | Toll-Like Receptor 9 | 1 | 2015 | 156 | 0.040 |
Why?
| | Cathepsin K | 2 | 2006 | 7 | 0.040 |
Why?
| | Luciferases | 2 | 2005 | 103 | 0.040 |
Why?
| | Ligands | 1 | 2015 | 343 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 1 | 2015 | 303 | 0.040 |
Why?
| | Gadolinium DTPA | 1 | 2014 | 51 | 0.040 |
Why?
| | X-Ray Microtomography | 1 | 2014 | 12 | 0.040 |
Why?
| | Genotype | 1 | 2015 | 471 | 0.040 |
Why?
| | Genes, Reporter | 2 | 2005 | 191 | 0.040 |
Why?
| | Histocytochemistry | 1 | 2014 | 46 | 0.040 |
Why?
| | Streptomycin | 1 | 1973 | 10 | 0.040 |
Why?
| | United States | 1 | 2003 | 3926 | 0.040 |
Why?
| | Hearing Disorders | 1 | 1973 | 2 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2014 | 32 | 0.040 |
Why?
| | Organometallic Compounds | 1 | 2014 | 65 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 118 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2016 | 608 | 0.040 |
Why?
| | Hindlimb | 1 | 2014 | 42 | 0.040 |
Why?
| | Vertigo | 1 | 1973 | 14 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 113 | 0.040 |
Why?
| | Vision Disorders | 1 | 1973 | 21 | 0.040 |
Why?
| | Up-Regulation | 2 | 2005 | 320 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 146 | 0.040 |
Why?
| | Random Allocation | 1 | 2014 | 162 | 0.040 |
Why?
| | Blotting, Western | 2 | 2005 | 543 | 0.040 |
Why?
| | Antigens, CD | 2 | 2006 | 288 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2016 | 961 | 0.040 |
Why?
| | Cell Movement | 1 | 2014 | 338 | 0.040 |
Why?
| | Fibroblasts | 2 | 2004 | 286 | 0.030 |
Why?
| | Arthrography | 1 | 2011 | 3 | 0.030 |
Why?
| | Registries | 1 | 2014 | 457 | 0.030 |
Why?
| | Remission Induction | 1 | 2011 | 88 | 0.030 |
Why?
| | Time Factors | 2 | 2009 | 2584 | 0.030 |
Why?
| | Pain Measurement | 1 | 2011 | 187 | 0.030 |
Why?
| | Recovery of Function | 1 | 2011 | 146 | 0.030 |
Why?
| | Epidemiologic Methods | 1 | 2009 | 65 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2009 | 58 | 0.030 |
Why?
| | Osteitis | 1 | 2009 | 1 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 64 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2011 | 256 | 0.030 |
Why?
| | Health Status | 1 | 2011 | 306 | 0.030 |
Why?
| | Postmenopause | 1 | 2009 | 216 | 0.030 |
Why?
| | Outcome Assessment (Health Care) | 1 | 2011 | 421 | 0.030 |
Why?
| | Quality of Life | 1 | 2011 | 415 | 0.030 |
Why?
| | Mutation | 2 | 2005 | 1735 | 0.030 |
Why?
| | Receptors, Calcitonin | 1 | 2006 | 1 | 0.020 |
Why?
| | Age Factors | 1 | 2009 | 1070 | 0.020 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2006 | 18 | 0.020 |
Why?
| | Fos-Related Antigen-2 | 1 | 2005 | 1 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2005 | 4 | 0.020 |
Why?
| | Smad1 Protein | 1 | 2005 | 6 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 1189 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2005 | 23 | 0.020 |
Why?
| | Tibia | 1 | 2005 | 31 | 0.020 |
Why?
| | Femur | 1 | 2005 | 30 | 0.020 |
Why?
| | Bone Morphogenetic Protein 2 | 1 | 2005 | 43 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2005 | 46 | 0.020 |
Why?
| | NFATC Transcription Factors | 1 | 2005 | 17 | 0.020 |
Why?
| | Bone Development | 1 | 2005 | 32 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2005 | 122 | 0.020 |
Why?
| | Cyclooxygenase 2 | 1 | 2005 | 54 | 0.020 |
Why?
| | Plasmids | 1 | 2005 | 246 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2005 | 141 | 0.020 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2005 | 134 | 0.020 |
Why?
| | Chemotaxis | 1 | 2004 | 38 | 0.020 |
Why?
| | Transcription Factor AP-1 | 1 | 2004 | 40 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 86 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2004 | 140 | 0.020 |
Why?
| | Transfection | 1 | 2005 | 640 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2004 | 183 | 0.020 |
Why?
| | Cell Cycle | 1 | 2005 | 339 | 0.020 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 43 | 0.020 |
Why?
| | DNA Damage | 1 | 2005 | 239 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2003 | 107 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2004 | 254 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2004 | 100 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2003 | 156 | 0.020 |
Why?
| | Tarsus, Animal | 1 | 2002 | 1 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2004 | 202 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2002 | 20 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2002 | 32 | 0.020 |
Why?
| | Immunization, Passive | 1 | 2002 | 84 | 0.020 |
Why?
| | Endopeptidases | 1 | 2002 | 63 | 0.020 |
Why?
| | Binding Sites | 1 | 2004 | 759 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2002 | 230 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2004 | 836 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2005 | 586 | 0.020 |
Why?
| | Pilot Projects | 1 | 2002 | 481 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2071 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2004 | 515 | 0.010 |
Why?
| | Apoptosis | 1 | 2005 | 860 | 0.010 |
Why?
| | Protein Binding | 1 | 2004 | 1225 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2005 | 687 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2002 | 426 | 0.010 |
Why?
| | Tooth Extraction | 1 | 1968 | 5 | 0.010 |
Why?
| | Surgical Wound Infection | 1 | 1968 | 60 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1968 | 375 | 0.010 |
Why?
| | Ear, Inner | 1 | 1973 | 4 | 0.010 |
Why?
| | Tuberculosis | 1 | 1973 | 121 | 0.010 |
Why?
| | Child, Preschool | 1 | 1973 | 1281 | 0.010 |
Why?
| | Child | 1 | 1973 | 2586 | 0.010 |
Why?
| | Adolescent | 1 | 1973 | 3894 | 0.010 |
Why?
| | Polymyxins | 1 | 1968 | 1 | 0.000 |
Why?
| | Tyrothricin | 1 | 1968 | 1 | 0.000 |
Why?
| | Tetracaine | 1 | 1968 | 6 | 0.000 |
Why?
| | Neomycin | 1 | 1968 | 8 | 0.000 |
Why?
| | Rats | 1 | 1968 | 1773 | 0.000 |
Why?
|
|
Gravallese's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|